Sangamo Therapeutics
SGMO
SGMO
131 hedge funds and large institutions have $68.2M invested in Sangamo Therapeutics in 2024 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 30 increasing their positions, 50 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
40% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 50
44% less call options, than puts
Call options by funds: $95K | Put options by funds: $170K
Holders
131
Holding in Top 10
–
Calls
$95K
Puts
$170K
Top Buyers
| 1 | +$11.4M | |
| 2 | +$5.18M | |
| 3 | +$839K | |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$298K |
| 5 |
Goldman Sachs
New York
|
+$250K |
Top Sellers
| 1 | -$1.09M | |
| 2 | -$1.08M | |
| 3 | -$860K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$790K |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$755K |